Moderna’s personalized cancer vaccine, mRNA-4157, in tandem with Merck’s Keytruda, went one for two in a small phase 1 study, missing the mark in colorectal cancer but shrinking tumors in some patients with head and neck cancer.

About a year and a half after receiving approval from the FDA as a first-line treatment for mesothelioma, Novocure has secured a CE mark for its Tumor Treating Fields therapy in Europe.

Shares in Five Prime Therapeutics jumped 300% on the back of data from a phase 2 trial that gave bemarituzumab as a front-line treatment to patients with advanced gastric and gastroesophageal junction cancers.

There’s an emerging business model in biotech town, and it’s called the Contract Vivarium (CV). This model has the benefit of giving companies direct oversight of their in vivo studies, allowing them to move faster while operationalizing every dollar of their seed financing.

A phase 3 trial of Amgen and AstraZeneca’s tezepelumab in severe asthma patients has met its primary endpoint. The thymic stromal lymphopoietin inhibitor drove reductions in exacerbations in patients with low levels of eosinophils, teeing the partners up to target a large, underserved portion of the asthma market.

TCR2 Therapeutics’ endgame was always to manufacture its T-cell therapies in-house. But while it works on its own commercial facilities, it’s getting a little help from Boston-area neighbor ElevateBio. The duo inked a manufacturing deal under which TCR2 will use ElevateBio’s centralized R&D and manufacturing site to produce TC-210, its mesothelin-targeting T-cell treatment, for a phase 2 study.

One day after Pfizer and BioNTech electrified the world with news the mRNA vaccine candidate the companies are developing against COVID-19 demonstrated 90% efficacy after an interim analysis, another vaccine developer, Sinovac, stumbled.

The FDA has cleared an app for the Apple Watch to help people suffering from nightmares or post-traumatic stress disorder (PTSD) get a better night’s sleep.

EGenesis has announced a research collaboration with Duke University’s school of medicine to help develop its xenotransplantation technology into a cell therapy for diabetes.

Bioelectric medicine is coming into its own as a combination or stand-alone therapy for a growing cohort of conditions. Big pharma has funded programs, international coalitions have formed and the National Institutes of Health (NIH) and the Defense Acquisition Research Agency (DARPA) each are making sizeable research investments. The field, panelists at a recent Demy-Colton Virtual Salon agreed, holds huge promise.